Sigma Acquisitions has agreed to buy UK clinical study recruitment and management specialist, Synexus, at 78 pence a share, valuing the company at about £18.1m (US$38m).
That is a 52.9% premium to the closing price of 51 pence per Synexus share on October 18 – the last day before Synexus admitted that it had received an approach.
Sigma has irrevocable acceptances of its offer by shareholders holding 54.18% of the equity in Synexus.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: